BPC-157 – Injection

BPC-157

Level A
BPC-157 – Injection

Editor: Dr. Jobby John, PharmD, FACA

Peptide Ledger review boards: Medical Review Board (Dr. Jobby John, PharmD, FACA; Dr. Richard Harris, MD, PharmD, MBA; Dr. Tracy Neal, MD; Dr. John Thoppil, MD; Dr. Natalie Kash, MD; Dr. Rahil Roopani, MD)Pharmacist Review Committee (Rachel Kuretich, PharmD, PharmD; Daniel Alonso, PharmD, PharmD; Christina Gunter, PharmD, PharmD; Patrick Gurley, PharmD, MS, PharmD, MS; Gyu-Hee Min, PharmD, PharmD)

Reviewed November 13, 2025

References are being re-verified against PubMed and will return with review dates.

A
Strong Evidence
Multiple randomized controlled trials and systematic reviews

Multiple randomized controlled trials and systematic reviews

BPC-157, short for *Body Protective Compound-157*, is generating intense buzz in the worlds of sports medicine and recovery. First identified in the early 1990s as a naturally occurring gastric peptide, BPC-157 is believed to help protect and repair tissues. Athletes and clinicians alike are increasingly curious about its potential to speed recovery from musculoskeletal injuries — but the science is still catching up.

A new *systematic review* published in the *HSS Journal* (2025) analyzed 36 studies on BPC-157 and found preclinical evidence of improved healing in muscle, tendon, ligament, and bone injuries, along with reduced inflammation. Despite this, BPC-157 remains unapproved by the FDA and is banned in professional sports.

Reference: HSS Journal Systematic Review 2025

Preclinical Safety:

  • No acute toxicity demonstrated
  • No mutagenicity or teratogenicity
  • Good tolerance in animal models

Human Safety:

  • Limited data - primarily retrospective reports
  • Long-term effects unknown
  • Drug interactions not well studied

Contraindications:

  • Active malignancy (theoretical concern - promotes angiogenesis)
  • Pregnancy/lactation (insufficient data)
  • Uncontrolled bleeding disorders
  • Known hypersensitivity to peptides

Warnings:

  • Use only under medical supervision
  • Source quality is critical
  • Monitor for adverse effects
  • Limit duration until more data available

Contraindications: * Hypersensitivity to BPC-157 or formulation excipients * Pregnancy, lactation, or children (safety unestablished) * Active malignancy or immunosuppression (use only under specialist advice) * Use only under supervision by a knowledgeable provider

⚠️ Important safety information above

Dosing considerations for clinicians

Dosing considerations are available to verified clinicians.

Sign in for clinician access

Coming to the Lake Hills Pharmacy pipeline.

Lake Hills Pharmacy is preparing peptide formulations in anticipation of regulatory guidance on compounded peptides. Planned strengths and dosing are shared with verified clinicians.

Sign in as a verified clinician to see planned strengths and dosing.

Contact us for more information

For Healthcare Providers

New to Lake Hills Pharmacy? Join our provider network. Lake Hills Pharmacy is preparing peptide programs as regulatory guidance on compounded peptides develops. Contact us for more information.

Contact us for more information

For Patients

Interested in BPC-157 – Injection? Connect with our medical team to discuss if this therapy is right for you.

or call us directly:

Clinical View: Complete drug monograph with evidence-based protocols. Switch to General View for patient-friendly information.

Important Information About Compounded Medications

These peptides are not FDA-approved but are commonly used by providers and patients under medical supervision. These statements have not been evaluated by the FDA. These products are not intended to diagnose, treat, cure, or prevent any disease. We provide evidence-based information from current research to help navigate this evolving field. Our goal is clear, evidence-based information for clinicians, with professional oversight at every step.

Lake Hills Pharmacy | Licensed 503A Compounding Pharmacy | Professional Medical Oversight Required